Canopy Growth Corporation
NASDAQ:CGC · NASDAQ Global Select
+$0.01 today
Vol 2.60M · Avg 9.97M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-52.6%
avg -77.9%
ROIC
-11.7%
avg -23.0%
ROA
-23.5%
avg -31.7%
Analysis
ROIC is currently the strongest return metric at -11.7% versus its period average of -23.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Luc Mongeau | Chief Executive Officer & Director | $1.50M | — | 58 | $802,992.00 | 0.19% |
Christelle Gedeon | Chief Business Development & Corporate Affairs Officer | $588,984.00 | — | 43 | $368,488.00 | 0.09% |
Thomas Carlton Stewart | Chief Accounting Officer & Chief Financial Officer | $344,361.00 | — | 44 | $246,665.00 | 0.06% |
Jason Green | Head of Agriculture - Hemp Division | — | — | — | — | — |
Miles Worne | Managing Director of European Markets | — | — | — | — | — |
Tyler Burns | Director of Investor Relations | — | — | — | — | — |
Chrissy McHardy | Senior Vice President of Human Resources | — | — | — | — | — |
Andrew Bevan | Senior Vice President of Medical Sales | — | — | — | — | — |
David Manner | Managing Director of Storz & Bickel GmbH | — | — | — | $72,048.00 | 0.02% |
Michael Perron | Chief Operating Officer | — | — | — | $54,814.00 | 0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$49,993.58
Sells
17
$222,230.73
Net Sentiment
$172,237.15
Net selling
Most Active
Yanofsky Theresa
4 transactions
1–10 of 18
Analysis
Insiders reported 1 buys worth $49,993.58 and 17 sells worth $222,230.73 over the last 12 months. That adds up to net selling of $172,237.15. Yanofsky Theresa was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +635.7% | +36.0% (17yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +635.7% over three years. Forward estimates point to Revenue at +36.0% (17yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$774.08M
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
$578.61M
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
$534.84M
Cabaletta Bio, Inc.
NASDAQ:CABA
$470.41M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$295.06M
Alpha Teknova, Inc.
NASDAQ:TKNO
$274.37M
Lifecore Biomedical, Inc.
NASDAQ:LFCR
$208.36M
Owens & Minor, Inc.
OMI
$207.07M
Aurora Cannabis Inc.
NASDAQ:ACB
$165.59M
Definitive Healthcare Corp.
NASDAQ:DH
$85.34M
Who manages CGC?
Canopy Growth Corporation (CGC) lists 10 active executives. The top listed executive is Jason Green, Head of Agriculture - Hemp Division.
Are CGC insiders buying or selling?
Recent insider activity shows net buying of $114.67M.
Explore More
Continue the stock analysis
Jump to another research area for this company.